Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin
The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding s...
Saved in:
| Published in | Annals of oncology Vol. 25; no. 1; pp. 257 - 264 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Elsevier Ltd
01.01.2014
Oxford University Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment.
A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute—Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc©), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20).
Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores.
None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined. |
|---|---|
| AbstractList | The perception of the severity and relevance of Chemotherapy Induced Peripheral Neurotoxicity (CIPN) is different for physicians and patients. This study provides the basis for a rationale use of different physician assessed scales and of European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20). The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment.BACKGROUNDThe different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment.A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc©), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20).PATIENTS AND METHODSA cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc©), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20).Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores.RESULTSPatients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores.None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined.CONCLUSIONNone of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined. The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although these two approaches might eventually lead to inconsistent, possibly conflicting interpretation, especially regarding sensory impairment. A cohort of 281 subjects with stable CIPN was evaluated with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC v. 2.0) sensory scale, the clinical Total Neuropathy Score (TNSc©), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) sensory sumscore (mISS) and the European Organization for Research and Treatment of Cancer CIPN specific self-report questionnaire (EORTC QOL-CIPN20). Patients' probability estimates showed that the EORTC QLQ-CIPN20 sensory score was overall more highly related to the NCI-CTC sensory score. However, the vibration perception item of the TNSc had a higher probability to be scored 0 for EORTC QLQ-CIPN20 scores lower than 35, as vibration score 2 for EORTC QLQ-CIPN20 scores between 35 and 50 and as grade 3 or 4 for EORTC QLQ-CIPN20 scores higher than 50. The linear models showed a significant trend between each mISS item and increasing EORTC QLQ-CIPN20 sensory scores. None of the clinical items had a perfect relationship with patients' perception, and most of the discrepancies stood in the intermediate levels of CIPN severity. Our data indicate that to achieve a comprehensive knowledge of CIPN including a reliable assessment of both the severity and the quality of CIPN-related sensory impairment, clinical and PRO measures should be always combined. |
| Author | Meijer, R.J. Dominguez Gonzalez, C. Ghignotti, I. Merkies, I.S.J. Mazzeo, A. Lanzani, F. Postma, T.J. Toscano, A. Briani, C. Brouwer, B. Penas Prado, M. Pace, A. Plasmati, R. Rossi, E. Velasco, R. Reni, L. Padua, L. Grant, R. Lalisang, R.I. Storey, D. Koeppen, S. Eurelings, M. Leandri, M. Kerrigan, S. Cavaletti, G. Grisold, W. Lindeck Pozza, E. Bakkers, M. Piras, B. Galiè, E. Granata, G. Fabbri, S. Cornblath, D.R. Valsecchi, M.G. Alberti, P. Piatti, M.L. Psimaras, D. Ricard, D. Dalla Torre, C. Pastorelli, F. Brell, J.M. Kalofonos, H.P. Cazzaniga, M. Campagnolo, M. Lucchetta, M. Vanhoutte, E.K. Bruna, J. Cortinovis, D. Galimberti, S. Heimans, J.J. Mattavelli, L. Boogerd, W. Dorsey, S.G. Tomasello, C. Schenone, A. Bidoli, P. Brandsma, D. Valsecchi, M.G Frigeni, B. Altavilla, G. Faber, C.G. Argyriou, A.A. Hense, J. Binda, D. |
| AuthorAffiliation | 14 Department of Neuro-Oncology , Netherlands Cancer Institute , Amsterdam , The Netherlands 5 Department of Neurology , Maastricht University Medical Center , Maastricht 11 Neurology Unit , National Cancer Institute Regina Elena , Rome 9 Service de Neurologie Mazarin , Hôpital de la Pitié-Salpêtrière, AP-HP , Paris 12 Department of Neurological, Psychiatric, Sensorial, Reconstructive and Rehabilitative Sciences , University of Padova , Padova , Italy 4 Department of Neurology , Spaarne Hospital , Hoofddorp 13 Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center , Maastricht 3 Department of Neurology , Johns Hopkins University School of Medicine , Baltimore , USA 6 Department of Neurology , VU University Medical Center , Amsterdam , The Netherlands 2 Center of Biostatistics for Clinical Epidemiology , Department of Health Sciences , University of Milano-Bicocca , Monza , Italy 10 Service de Neurolog |
| AuthorAffiliation_xml | – name: 7 Unit of Neuro-Oncology, Department of Neurology , University Hospital of Bellvitge-ICO Duran I Reynals , L'Hospitalet , Barcelona , Spain – name: 10 Service de Neurologie , Hôpital du Val-de-Grâce, Service de Santé des Armées , Paris , France – name: 15 Department of Neurology and West German Cancer Center , University of Essen , Essen , Germany – name: 17 Department of Neuroscience, Ophthalmology and Genetic , Center of Excellence for Biomedical Research , University of Genova , Genova , Italy – name: 8 Division of Clinical Oncology, Department of Medicine , University Hospital of Patras , Patras , Greece – name: 16 Edinburgh Centre for Neuro-Oncology and Edinburgh Cancer Research Center , Western General Hospital , Edinburgh , UK – name: 1 Department of Surgery and Translational Medicine – name: 4 Department of Neurology , Spaarne Hospital , Hoofddorp – name: 5 Department of Neurology , Maastricht University Medical Center , Maastricht – name: 2 Center of Biostatistics for Clinical Epidemiology , Department of Health Sciences , University of Milano-Bicocca , Monza , Italy – name: 6 Department of Neurology , VU University Medical Center , Amsterdam , The Netherlands – name: 13 Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center , Maastricht – name: 12 Department of Neurological, Psychiatric, Sensorial, Reconstructive and Rehabilitative Sciences , University of Padova , Padova , Italy – name: 14 Department of Neuro-Oncology , Netherlands Cancer Institute , Amsterdam , The Netherlands – name: 9 Service de Neurologie Mazarin , Hôpital de la Pitié-Salpêtrière, AP-HP , Paris – name: 3 Department of Neurology , Johns Hopkins University School of Medicine , Baltimore , USA – name: 11 Neurology Unit , National Cancer Institute Regina Elena , Rome |
| Author_xml | – sequence: 1 givenname: P. surname: Alberti fullname: Alberti, P. organization: Department of Surgery and Translational Medicine – sequence: 2 givenname: E. surname: Rossi fullname: Rossi, E. organization: Center of Biostatistics for Clinical Epidemiology, Department of Health Sciences, University of Milano-Bicocca, Monza, Italy – sequence: 3 givenname: D.R. surname: Cornblath fullname: Cornblath, D.R. organization: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA – sequence: 4 givenname: I.S.J. surname: Merkies fullname: Merkies, I.S.J. organization: Department of Neurology, Spaarne Hospital, Hoofddorp – sequence: 5 givenname: T.J. surname: Postma fullname: Postma, T.J. organization: Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands – sequence: 6 givenname: B. surname: Frigeni fullname: Frigeni, B. organization: Department of Surgery and Translational Medicine – sequence: 7 givenname: J. surname: Bruna fullname: Bruna, J. organization: Unit of Neuro-Oncology, Department of Neurology, University Hospital of Bellvitge-ICO Duran I Reynals, L'Hospitalet, Barcelona, Spain – sequence: 8 givenname: R. surname: Velasco fullname: Velasco, R. organization: Unit of Neuro-Oncology, Department of Neurology, University Hospital of Bellvitge-ICO Duran I Reynals, L'Hospitalet, Barcelona, Spain – sequence: 9 givenname: A.A. surname: Argyriou fullname: Argyriou, A.A. organization: Division of Clinical Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece – sequence: 10 givenname: H.P. surname: Kalofonos fullname: Kalofonos, H.P. organization: Division of Clinical Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece – sequence: 11 givenname: D. surname: Psimaras fullname: Psimaras, D. organization: Service de Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris – sequence: 12 givenname: D. surname: Ricard fullname: Ricard, D. organization: Service de Neurologie, Hôpital du Val-de-Grâce, Service de Santé des Armées, Paris, France – sequence: 13 givenname: A. surname: Pace fullname: Pace, A. organization: Neurology Unit, National Cancer Institute Regina Elena, Rome – sequence: 14 givenname: E. surname: Galiè fullname: Galiè, E. organization: Neurology Unit, National Cancer Institute Regina Elena, Rome – sequence: 15 givenname: C. surname: Briani fullname: Briani, C. organization: Department of Neurological, Psychiatric, Sensorial, Reconstructive and Rehabilitative Sciences, University of Padova, Padova, Italy – sequence: 16 givenname: C. surname: Dalla Torre fullname: Dalla Torre, C. organization: Department of Neurological, Psychiatric, Sensorial, Reconstructive and Rehabilitative Sciences, University of Padova, Padova, Italy – sequence: 17 givenname: C.G. surname: Faber fullname: Faber, C.G. organization: Department of Neurology, Maastricht University Medical Center, Maastricht – sequence: 18 givenname: R.I. surname: Lalisang fullname: Lalisang, R.I. organization: Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht – sequence: 19 givenname: W. surname: Boogerd fullname: Boogerd, W. organization: Department of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands – sequence: 20 givenname: D. surname: Brandsma fullname: Brandsma, D. organization: Department of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands – sequence: 21 givenname: S. surname: Koeppen fullname: Koeppen, S. organization: Department of Neurology and West German Cancer Center, University of Essen, Essen, Germany – sequence: 22 givenname: J. surname: Hense fullname: Hense, J. organization: Department of Neurology and West German Cancer Center, University of Essen, Essen, Germany – sequence: 23 givenname: D. surname: Storey fullname: Storey, D. organization: Edinburgh Centre for Neuro-Oncology and Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK – sequence: 24 givenname: S. surname: Kerrigan fullname: Kerrigan, S. organization: Edinburgh Centre for Neuro-Oncology and Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK – sequence: 25 givenname: A. surname: Schenone fullname: Schenone, A. organization: Department of Neuroscience, Ophthalmology and Genetic, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy – sequence: 26 givenname: S. surname: Fabbri fullname: Fabbri, S. organization: Department of Neuroscience, Ophthalmology and Genetic, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy – sequence: 27 givenname: M.G. surname: Valsecchi fullname: Valsecchi, M.G. organization: Center of Biostatistics for Clinical Epidemiology, Department of Health Sciences, University of Milano-Bicocca, Monza, Italy – sequence: 28 givenname: G. surname: Cavaletti fullname: Cavaletti, G. email: guido.cavaletti@unimib.it organization: Department of Surgery and Translational Medicine – sequence: 29 givenname: G. surname: Cavaletti fullname: Cavaletti, G. – sequence: 30 givenname: D.R. surname: Cornblath fullname: Cornblath, D.R. – sequence: 31 givenname: I.S.J. surname: Merkies fullname: Merkies, I.S.J. – sequence: 32 givenname: T.J. surname: Postma fullname: Postma, T.J. – sequence: 33 givenname: M.G surname: Valsecchi fullname: Valsecchi, M.G – sequence: 34 givenname: S. surname: Galimberti fullname: Galimberti, S. – sequence: 35 givenname: E. surname: Rossi fullname: Rossi, E. – sequence: 37 givenname: B. surname: Frigeni fullname: Frigeni, B. – sequence: 38 givenname: F. surname: Lanzani fullname: Lanzani, F. – sequence: 39 givenname: L. surname: Mattavelli fullname: Mattavelli, L. – sequence: 40 givenname: M.L. surname: Piatti fullname: Piatti, M.L. – sequence: 41 givenname: P. surname: Alberti fullname: Alberti, P. – sequence: 42 givenname: D. surname: Binda fullname: Binda, D. – sequence: 43 givenname: P. surname: Bidoli fullname: Bidoli, P. – sequence: 44 givenname: M. surname: Cazzaniga fullname: Cazzaniga, M. – sequence: 45 givenname: D. surname: Cortinovis fullname: Cortinovis, D. – sequence: 46 givenname: J. surname: Bruna fullname: Bruna, J. – sequence: 47 givenname: R. surname: Velasco fullname: Velasco, R. – sequence: 48 givenname: A.A. surname: Argyriou fullname: Argyriou, A.A. – sequence: 49 givenname: H.P. surname: Kalofonos fullname: Kalofonos, H.P. – sequence: 50 givenname: D. surname: Psimaras fullname: Psimaras, D. – sequence: 51 givenname: D. surname: Ricard fullname: Ricard, D. – sequence: 52 givenname: A. surname: Pace fullname: Pace, A. – sequence: 53 givenname: E. surname: Galiè fullname: Galiè, E. – sequence: 54 givenname: C. surname: Briani fullname: Briani, C. – sequence: 55 givenname: M. surname: Lucchetta fullname: Lucchetta, M. – sequence: 56 givenname: M. surname: Campagnolo fullname: Campagnolo, M. – sequence: 57 givenname: C. surname: Dalla Torre fullname: Dalla Torre, C. – sequence: 59 givenname: C.G. surname: Faber fullname: Faber, C.G. – sequence: 61 givenname: E.K. surname: Vanhoutte fullname: Vanhoutte, E.K. – sequence: 62 givenname: M. surname: Bakkers fullname: Bakkers, M. – sequence: 63 givenname: B. surname: Brouwer fullname: Brouwer, B. – sequence: 64 givenname: R.I. surname: Lalisang fullname: Lalisang, R.I. – sequence: 65 givenname: W. surname: Boogerd fullname: Boogerd, W. – sequence: 66 givenname: D. surname: Brandsma fullname: Brandsma, D. – sequence: 67 givenname: S. surname: Koeppen fullname: Koeppen, S. – sequence: 68 givenname: J. surname: Hense fullname: Hense, J. – sequence: 69 givenname: R. surname: Grant fullname: Grant, R. – sequence: 70 givenname: D. surname: Storey fullname: Storey, D. – sequence: 71 givenname: S. surname: Kerrigan fullname: Kerrigan, S. – sequence: 72 givenname: A. surname: Schenone fullname: Schenone, A. – sequence: 73 givenname: L. surname: Reni fullname: Reni, L. – sequence: 74 givenname: B. surname: Piras fullname: Piras, B. – sequence: 75 givenname: S. surname: Fabbri fullname: Fabbri, S. – sequence: 76 givenname: L. surname: Padua fullname: Padua, L. – sequence: 77 givenname: G. surname: Granata fullname: Granata, G. – sequence: 78 givenname: M. surname: Leandri fullname: Leandri, M. – sequence: 79 givenname: I. surname: Ghignotti fullname: Ghignotti, I. – sequence: 80 givenname: R. surname: Plasmati fullname: Plasmati, R. – sequence: 81 givenname: F. surname: Pastorelli fullname: Pastorelli, F. – sequence: 83 givenname: J.J. surname: Heimans fullname: Heimans, J.J. – sequence: 84 givenname: M. surname: Eurelings fullname: Eurelings, M. – sequence: 85 givenname: R.J. surname: Meijer fullname: Meijer, R.J. – sequence: 86 givenname: W. surname: Grisold fullname: Grisold, W. – sequence: 87 givenname: E. surname: Lindeck Pozza fullname: Lindeck Pozza, E. – sequence: 88 givenname: A. surname: Mazzeo fullname: Mazzeo, A. – sequence: 89 givenname: A. surname: Toscano fullname: Toscano, A. – sequence: 90 givenname: C. surname: Tomasello fullname: Tomasello, C. – sequence: 91 givenname: G. surname: Altavilla fullname: Altavilla, G. – sequence: 92 givenname: M. surname: Penas Prado fullname: Penas Prado, M. – sequence: 93 givenname: C. surname: Dominguez Gonzalez fullname: Dominguez Gonzalez, C. – sequence: 94 givenname: S.G. surname: Dorsey fullname: Dorsey, S.G. – sequence: 95 givenname: J.M. surname: Brell fullname: Brell, J.M. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28133748$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24256846$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kk2LFDEQhoOsuLOrR6-Si-Cl3XSS_vIgyLJ-wIIe9Byq09VOpDtpk_Tq_Ij9z9Yws37BQiCQeuqtStV7xk588MjY01K8LEWnLsDTg72Yh6xF94Btyqruilbo8oRtRCdV0VRKn7KzlL4JIepOdo_YqdSyqltdb9jtp-0uOevAF5AS0hk4-IEvkB36XERcQsz0GNZsw4x8RkhrxMSd53aLc8hbjLDsCueH1RKY0KcQd3zB6JZ9bOIe1xhy-El18u4Vzz8CT24gjTBySucJSNgG5x-zhyNMCZ8c73P25e3V58v3xfXHdx8u31wXtlJlLsa2LHuJqJRUtRyw6mvQuq3GBmCQgLLRuhFC2l5rqDT0CLLFXqu-lQCiUefs9UF3WfsZB0s_pT7NEt0McWcCOPNvxLut-RpujGrrVklJAi-OAjF8XzFlM7tkcZrAY1iTKXUnqIOmqgh99net30XudkDA8yMAycI0RvDWpT9cWyrV6JY4deBsDClFHA2Nk9YU9i26yZTC7B1hDo4wB0dQVvFf1p3wfXxz4JHmf-MwmmTJCbRZF9FmMwR3T-Yv3cnUKQ |
| CitedBy_id | crossref_primary_10_1007_s00520_014_2289_x crossref_primary_10_1016_j_jns_2023_122862 crossref_primary_10_1016_j_vascn_2016_09_003 crossref_primary_10_1186_s43094_024_00691_5 crossref_primary_10_1002_ana_24265 crossref_primary_10_1111_jns_12333 crossref_primary_10_1111_jns5_12073 crossref_primary_10_1177_10781552251314348 crossref_primary_10_3390_nu10040398 crossref_primary_10_1111_fct_12095 crossref_primary_10_1177_1534735419888584 crossref_primary_10_1002_cam4_4328 crossref_primary_10_1007_s00520_020_05299_y crossref_primary_10_1136_rapm_2025_106586 crossref_primary_10_1038_leu_2016_374 crossref_primary_10_1002_onco_13697 crossref_primary_10_1016_j_jpainsymman_2019_07_021 crossref_primary_10_1016_j_ygyno_2015_11_011 crossref_primary_10_1016_j_ygyno_2016_11_013 crossref_primary_10_1007_s00520_014_2408_8 crossref_primary_10_1097_CIN_0000000000000320 crossref_primary_10_1016_j_ctrv_2021_102241 crossref_primary_10_1007_s00520_024_08627_8 crossref_primary_10_1080_0284186X_2016_1197420 crossref_primary_10_3389_fphar_2021_744085 crossref_primary_10_1016_j_pec_2019_04_012 crossref_primary_10_5306_wjco_v8_i4_329 crossref_primary_10_3389_fpain_2022_864910 crossref_primary_10_1016_j_jpain_2015_07_002 crossref_primary_10_1136_bmjopen_2018_027770 crossref_primary_10_1188_17_ONF_580_588 crossref_primary_10_1016_j_clinph_2020_04_013 crossref_primary_10_1016_j_jpain_2016_10_020 crossref_primary_10_1186_s12885_021_08884_4 crossref_primary_10_1007_s00520_016_3373_1 crossref_primary_10_14260_jemds_2020_689 crossref_primary_10_3390_jcm9082400 crossref_primary_10_1097_WCO_0000000000000724 crossref_primary_10_1016_j_neurol_2020_11_001 crossref_primary_10_1186_s12885_023_11079_8 crossref_primary_10_1080_17425255_2017_1258400 crossref_primary_10_1212_WNL_0000000000012300 crossref_primary_10_1515_med_2023_0696 crossref_primary_10_3390_curroncol31120577 crossref_primary_10_1007_s00520_020_05345_9 crossref_primary_10_1080_14656566_2017_1415326 crossref_primary_10_1186_s12885_021_08240_6 crossref_primary_10_1080_17425255_2019_1622679 crossref_primary_10_1097_NCC_0000000000000596 crossref_primary_10_14694_EdBook_AM_2015_35_e553 crossref_primary_10_1097_NCC_0000000000001286 crossref_primary_10_1007_s00520_024_08493_4 crossref_primary_10_1111_jns_12306 crossref_primary_10_1093_annonc_mdx491 crossref_primary_10_1093_jnci_djx178 crossref_primary_10_1186_s12885_022_09806_8 crossref_primary_10_1007_s00520_017_3780_y crossref_primary_10_1016_j_scr_2015_12_025 crossref_primary_10_1080_07420528_2025_2460643 crossref_primary_10_1007_s11136_017_1626_1 crossref_primary_10_1177_1073274818756608 crossref_primary_10_3390_cancers13236125 crossref_primary_10_1007_s00520_020_05796_0 crossref_primary_10_1016_j_ejca_2016_09_020 crossref_primary_10_1093_bja_aex229 crossref_primary_10_3389_fneur_2017_00223 crossref_primary_10_1016_j_annonc_2020_07_003 crossref_primary_10_1007_s00520_024_08807_6 crossref_primary_10_1097_01893697_201533030_00005 crossref_primary_10_3390_genes14010170 crossref_primary_10_1007_s10549_017_4437_8 crossref_primary_10_1200_JCO_2014_55_1846 crossref_primary_10_1111_ajco_13834 crossref_primary_10_2217_fon_14_60 crossref_primary_10_1634_theoncologist_2014_0044 crossref_primary_10_1007_s00520_020_05928_6 crossref_primary_10_1007_s00520_019_04680_w crossref_primary_10_3390_cancers12061370 crossref_primary_10_1007_s00520_016_3297_9 crossref_primary_10_1007_s00520_018_4553_y crossref_primary_10_1007_s11060_015_2049_x crossref_primary_10_1371_journal_pone_0183845 crossref_primary_10_3390_toxics3020152 crossref_primary_10_1212_WNL_0000000000006083 crossref_primary_10_6004_jnccn_2019_7290 crossref_primary_10_1016_j_brainresbull_2023_110769 crossref_primary_10_1002_cnr2_1677 crossref_primary_10_1097_j_pain_0000000000000743 crossref_primary_10_1186_s12967_022_03754_4 crossref_primary_10_1111_ecc_13240 crossref_primary_10_1007_s11764_019_00769_7 crossref_primary_10_1111_ajco_13293 crossref_primary_10_1007_s00520_020_05891_2 crossref_primary_10_1007_s00540_017_2362_y crossref_primary_10_1097_CCO_0000000000000139 crossref_primary_10_3390_cancers15164191 crossref_primary_10_1007_s11136_022_03154_7 crossref_primary_10_2174_1568009621666210720142542 crossref_primary_10_1016_j_bulcan_2018_07_009 crossref_primary_10_1001_jamanetworkopen_2024_24139 crossref_primary_10_1016_j_clinph_2020_02_028 crossref_primary_10_1016_j_celrep_2023_113386 crossref_primary_10_1097_SPC_0000000000000684 crossref_primary_10_1007_s00520_021_06196_8 crossref_primary_10_1016_j_jns_2015_06_056 crossref_primary_10_1007_s00520_017_3772_y crossref_primary_10_3389_fphar_2021_637593 crossref_primary_10_1007_s13311_017_0572_5 crossref_primary_10_1016_j_ygyno_2020_05_026 crossref_primary_10_1007_s00520_023_08301_5 crossref_primary_10_1097_j_pain_0000000000000404 crossref_primary_10_1177_10998004231209444 crossref_primary_10_1002_jso_25254 crossref_primary_10_1097_NCC_0000000000000674 crossref_primary_10_1007_s00405_021_07234_1 crossref_primary_10_1007_s15015_014_1153_7 crossref_primary_10_1016_S1470_2045_16_00152_2 crossref_primary_10_1093_pm_pnaa407 crossref_primary_10_1016_j_clinph_2023_08_002 crossref_primary_10_1007_s11888_014_0230_9 crossref_primary_10_1001_jamanetworkopen_2022_39788 crossref_primary_10_1212_WNL_0000000000004272 crossref_primary_10_1007_s00520_017_3764_y crossref_primary_10_1080_14737175_2022_2018300 crossref_primary_10_1080_17425255_2021_1842873 crossref_primary_10_1111_jns_12226 crossref_primary_10_1080_0284186X_2021_2007283 crossref_primary_10_1111_ene_16457 crossref_primary_10_1007_s00520_025_09282_3 crossref_primary_10_1186_s12885_019_5302_4 crossref_primary_10_1016_j_pmr_2018_06_006 crossref_primary_10_2147_PPA_S501409 crossref_primary_10_1016_j_ctarc_2021_100420 crossref_primary_10_1007_s00520_019_04781_6 crossref_primary_10_37349_ent_2022_00020 crossref_primary_10_1007_s11136_017_1635_0 crossref_primary_10_1080_09291016_2024_2418654 crossref_primary_10_1097_WCO_0000000000000234 crossref_primary_10_1186_s12885_018_5093_z crossref_primary_10_1007_s40487_021_00168_y crossref_primary_10_1111_bcpt_12262 crossref_primary_10_1007_s00520_024_08484_5 crossref_primary_10_3389_fonc_2024_1420518 |
| Cites_doi | 10.1111/j.1529-8027.2007.00141.x 10.1093/annonc/mds329 10.1007/s10147-011-0298-z 10.1007/s10549-010-1278-0 10.1093/neuonc/nos203 10.1212/WNL.53.8.1660 10.1136/jnnp.2005.076174 10.1093/annonc/mdq721 10.1007/s00520-012-1428-5 10.1093/jnci/85.5.365 10.1111/j.1529-8027.2011.00351.x 10.1007/s00520-011-1141-9 10.1093/annonc/mdt173 10.1016/j.ejca.2005.02.012 10.1136/jnnp.2007.139220 10.1007/s11136-013-0379-8 10.1016/j.ejca.2009.12.008 10.1212/01.WNL.0000092015.03923.19 10.2307/2529310 10.1136/jnnp.65.5.743 |
| ContentType | Journal Article |
| Contributor | Kalofonos, Hp Heimans, Jj Merkies, Isj Plasmati, R Hense, J Fabbri, S Faber, Cg Reni, L Brell, Jm Pace, A Grant, R Storey, D Cazzaniga, M Postma, T J Velasco, R Toscano, A Bruna, J Lanzani, F Lucchetta, M Briani, C Dominguez Gonzalez, C Koeppen, S Bidoli, P Grisold, W Vanhoutte, Ek Dorsey, Sg Ricard, D Ghignotti, I Pastorelli, F Penas Prado, M Valsecchi, M G Alberti, P Piatti, Ml Schenone, A Leandri, M Merkies, I S J Galiè, E Kerrigan, S Cornblath, D R Granata, G Tomasello, C Altavilla, G Brouwer, B Frigeni, B Postma, Tj Boogerd, W Psimaras, D Eurelings, M Lindeck Pozza, E Cortinovis, D Brandsma, D Piras, B Padua, L Meijer, Rj Cavaletti, G Lalisang, Ri Argyriou, Aa Dalla Torre, C Campagnolo, M Binda, D Rossi, E Mattavelli, L Bakkers, M Galimberti, S Mazzeo, A |
| Contributor_xml | – sequence: 1 givenname: G surname: Cavaletti fullname: Cavaletti, G – sequence: 2 givenname: D R surname: Cornblath fullname: Cornblath, D R – sequence: 3 givenname: I S J surname: Merkies fullname: Merkies, I S J – sequence: 4 givenname: T J surname: Postma fullname: Postma, T J – sequence: 5 givenname: M G surname: Valsecchi fullname: Valsecchi, M G – sequence: 6 givenname: S surname: Galimberti fullname: Galimberti, S – sequence: 7 givenname: E surname: Rossi fullname: Rossi, E – sequence: 8 givenname: B surname: Frigeni fullname: Frigeni, B – sequence: 9 givenname: F surname: Lanzani fullname: Lanzani, F – sequence: 10 givenname: L surname: Mattavelli fullname: Mattavelli, L – sequence: 11 givenname: Ml surname: Piatti fullname: Piatti, Ml – sequence: 12 givenname: P surname: Alberti fullname: Alberti, P – sequence: 13 givenname: D surname: Binda fullname: Binda, D – sequence: 14 givenname: P surname: Bidoli fullname: Bidoli, P – sequence: 15 givenname: M surname: Cazzaniga fullname: Cazzaniga, M – sequence: 16 givenname: D surname: Cortinovis fullname: Cortinovis, D – sequence: 17 givenname: J surname: Bruna fullname: Bruna, J – sequence: 18 givenname: R surname: Velasco fullname: Velasco, R – sequence: 19 givenname: Aa surname: Argyriou fullname: Argyriou, Aa – sequence: 20 givenname: Hp surname: Kalofonos fullname: Kalofonos, Hp – sequence: 21 givenname: D surname: Psimaras fullname: Psimaras, D – sequence: 22 givenname: D surname: Ricard fullname: Ricard, D – sequence: 23 givenname: A surname: Pace fullname: Pace, A – sequence: 24 givenname: E surname: Galiè fullname: Galiè, E – sequence: 25 givenname: C surname: Briani fullname: Briani, C – sequence: 26 givenname: M surname: Lucchetta fullname: Lucchetta, M – sequence: 27 givenname: M surname: Campagnolo fullname: Campagnolo, M – sequence: 28 givenname: C surname: Dalla Torre fullname: Dalla Torre, C – sequence: 29 givenname: Isj surname: Merkies fullname: Merkies, Isj – sequence: 30 givenname: Cg surname: Faber fullname: Faber, Cg – sequence: 31 givenname: Ek surname: Vanhoutte fullname: Vanhoutte, Ek – sequence: 32 givenname: M surname: Bakkers fullname: Bakkers, M – sequence: 33 givenname: B surname: Brouwer fullname: Brouwer, B – sequence: 34 givenname: Ri surname: Lalisang fullname: Lalisang, Ri – sequence: 35 givenname: W surname: Boogerd fullname: Boogerd, W – sequence: 36 givenname: D surname: Brandsma fullname: Brandsma, D – sequence: 37 givenname: S surname: Koeppen fullname: Koeppen, S – sequence: 38 givenname: J surname: Hense fullname: Hense, J – sequence: 39 givenname: R surname: Grant fullname: Grant, R – sequence: 40 givenname: D surname: Storey fullname: Storey, D – sequence: 41 givenname: S surname: Kerrigan fullname: Kerrigan, S – sequence: 42 givenname: A surname: Schenone fullname: Schenone, A – sequence: 43 givenname: L surname: Reni fullname: Reni, L – sequence: 44 givenname: B surname: Piras fullname: Piras, B – sequence: 45 givenname: S surname: Fabbri fullname: Fabbri, S – sequence: 46 givenname: L surname: Padua fullname: Padua, L – sequence: 47 givenname: G surname: Granata fullname: Granata, G – sequence: 48 givenname: M surname: Leandri fullname: Leandri, M – sequence: 49 givenname: I surname: Ghignotti fullname: Ghignotti, I – sequence: 50 givenname: R surname: Plasmati fullname: Plasmati, R – sequence: 51 givenname: F surname: Pastorelli fullname: Pastorelli, F – sequence: 52 givenname: Tj surname: Postma fullname: Postma, Tj – sequence: 53 givenname: Jj surname: Heimans fullname: Heimans, Jj – sequence: 54 givenname: M surname: Eurelings fullname: Eurelings, M – sequence: 55 givenname: Rj surname: Meijer fullname: Meijer, Rj – sequence: 56 givenname: W surname: Grisold fullname: Grisold, W – sequence: 57 givenname: E surname: Lindeck Pozza fullname: Lindeck Pozza, E – sequence: 58 givenname: A surname: Mazzeo fullname: Mazzeo, A – sequence: 59 givenname: A surname: Toscano fullname: Toscano, A – sequence: 60 givenname: C surname: Tomasello fullname: Tomasello, C – sequence: 61 givenname: G surname: Altavilla fullname: Altavilla, G – sequence: 62 givenname: M surname: Penas Prado fullname: Penas Prado, M – sequence: 63 givenname: C surname: Dominguez Gonzalez fullname: Dominguez Gonzalez, C – sequence: 64 givenname: Sg surname: Dorsey fullname: Dorsey, Sg – sequence: 65 givenname: Jm surname: Brell fullname: Brell, Jm |
| Copyright | 2013 European Society for Medical Oncology 2015 INIST-CNRS The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2013 |
| Copyright_xml | – notice: 2013 European Society for Medical Oncology – notice: 2015 INIST-CNRS – notice: The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2013 |
| CorporateAuthor | the CI-PeriNomS Group CI-PeriNomS Group |
| CorporateAuthor_xml | – name: the CI-PeriNomS Group – name: CI-PeriNomS Group |
| DBID | 6I. AAFTH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1093/annonc/mdt409 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1569-8041 |
| EndPage | 264 |
| ExternalDocumentID | PMC3868322 24256846 28133748 10_1093_annonc_mdt409 S0923753419359356 |
| Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NINR NIH HHS grantid: P30 NR011396 |
| GroupedDBID | --- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 0U7 1TH 23M 2WC 4.4 482 48X 53G 5GY 5VS 5WA 6.Y 6I. 6J9 70D AABJS AABMN AAEDW AAESY AAFTH AAIAV AAIYJ AAJKP AAJQQ AAKAS AAKUH AAMVS AAOGV AAPNW AAUQX AAXUO ABEUO ABIXL ABJNI ABKDP ABLJU ABNKS ABOCM ABQLI ABQTQ ABSAR ABSMQ ABVKL ABZBJ ACGFO ACGFS ACIMA ACMRT ACPQN ACPRK ACUFI ACUTO ADBBV ADEIU ADEYI ADHKW ADHZD ADJQC ADOCK ADORX ADQLU ADRIX ADRTK ADYVW ADZCM ADZXQ AEGPL AEGXH AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AEWNT AFIYH AFOFC AFXEN AGINJ AGKEF AGKRT AGSYK AHMBA AHXPO AIAGR AIJHB AIKOY AITUG ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN AQKUS ASMCH ASPBG ATTQO AVWKF AWCFO AXUDD AZFZN AZQFJ BAWUL BAYMD BEYMZ BGNMA BGYMP BHONS BTRTY BVRKM BZKNY C1A CAG CASEJ CDBKE CKLRP COF CS3 CZ4 DAKXR DIK DILTD DL5 DPORF DPPUQ D~K E3Z EBS EE~ EJD EX3 F9B FDB FEDTE GJXCC GX1 H5~ HAR HVGLF HW0 HZ~ I09 IH2 IHE IOX J21 KAQDR KC5 KDC KOM KOP KQ8 KSI KSN LAK M-Z M41 M49 M4Y MBLQV MHKGH N9A NCXOZ NGC NOYVH NTWIH NU- NU0 NVLIB O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RNI ROL ROX ROZ RPX RW1 RXO RZC RZE RZF RZO SDH TCURE TEORI TJX TMA TR2 U2A W8F WOQ WOW X7H YAYTL YFH YKOAZ ZKX ZXP ~91 AAGQS AALRI AAYWO AAYXX ABNGD ACUKT ACVFH ADCNI ADVLN AEHUL AEUPX AFETI AFJKZ AFPUW AFSHK AGCQF AGQPQ AIGII AKBMS AKRWK AKYEP APXCP CITATION H13 IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM EFKBS |
| ID | FETCH-LOGICAL-c531t-f811b2ee332362de5b6a4485f7aad2ae27447002cb44a54abea28eb43b82aa073 |
| ISSN | 0923-7534 1569-8041 |
| IngestDate | Thu Aug 21 14:05:20 EDT 2025 Fri Jul 11 03:39:12 EDT 2025 Wed Feb 19 02:32:20 EST 2025 Wed Apr 02 07:28:56 EDT 2025 Tue Jul 01 01:15:41 EDT 2025 Thu Apr 24 22:56:56 EDT 2025 Fri Feb 23 02:46:11 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | assessment neuropathy neurotoxicity chemotherapy patient-reported outcome measure Human Evaluation Nervous system diseases Prognosis Health staff Toxicity Physician Neuropathy Chemotherapy Neurotoxicity Treatment |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c531t-f811b2ee332362de5b6a4485f7aad2ae27447002cb44a54abea28eb43b82aa073 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 See appendix for the complete list of participating centers and investigators. Equally contributed to the paper. |
| OpenAccessLink | https://dx.doi.org/10.1093/annonc/mdt409 |
| PMID | 24256846 |
| PQID | 1490700755 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3868322 proquest_miscellaneous_1490700755 pubmed_primary_24256846 pascalfrancis_primary_28133748 crossref_citationtrail_10_1093_annonc_mdt409 crossref_primary_10_1093_annonc_mdt409 elsevier_sciencedirect_doi_10_1093_annonc_mdt409 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-01-01 |
| PublicationDateYYYYMMDD | 2014-01-01 |
| PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: England |
| PublicationTitle | Annals of oncology |
| PublicationTitleAlternate | Ann Oncol |
| PublicationYear | 2014 |
| Publisher | Elsevier Ltd Oxford University Press |
| Publisher_xml | – name: Elsevier Ltd – name: Oxford University Press |
| References | Cavaletti, Bogliun, Marzorati (bb0030) 2003; 61 Cavaletti, Cornblath, Merkies (bb0045) 2013; 24 Postma, Aaronson, Heimans (bb0090) 2005; 41 Hershman, Weimer, Wang (bb0055) 2011; 125 Cavaletti, Frigeni, Lanzani (bb0025) 2007; 12 Postma (bb0105) 2013; 24 Luckett, King, Butow (bb0085) 2011; 22 Martina, van Koningsveld, Schmitz (bb0070) 1998; 65 Cornblath, Chaudhry, Carter (bb0035) 1999; 53 Grisold, Cavaletti, Windebank (bb0010) 2012; 14 Bennett, Park, Lin (bb0060) 2012; 20 Aaronson, Ahmedzai, Bergman (bb0050) 1993; 85 Merkies, Schmitz (bb0040) 2006; 77 van Nes, Faber, Hamers (bb0075) 2008; 79 Cavaletti, Frigeni, Lanzani (bb0020) 2010; 46 Lavoie Smith, Barton, Qin (bb0100) 2013 Frigeni, Piatti, Lanzani (bb0015) 2011; 16 Inoue, Ishida, Sano (bb0065) 2012; 17 Landis, Koch (bb0080) 1977; 33 Wolf, Barton, Qin (bb0095) 2011; 20 Cavaletti (10.1093/annonc/mdt409_bb0045) 2013; 24 Cavaletti (10.1093/annonc/mdt409_bb0020) 2010; 46 Landis (10.1093/annonc/mdt409_bb0080) 1977; 33 Cavaletti (10.1093/annonc/mdt409_bb0025) 2007; 12 Wolf (10.1093/annonc/mdt409_bb0095) 2011; 20 Luckett (10.1093/annonc/mdt409_bb0085) 2011; 22 van Nes (10.1093/annonc/mdt409_bb0075) 2008; 79 Frigeni (10.1093/annonc/mdt409_bb0015) 2011; 16 Hershman (10.1093/annonc/mdt409_bb0055) 2011; 125 Bennett (10.1093/annonc/mdt409_bb0060) 2012; 20 Lavoie Smith (10.1093/annonc/mdt409_bb0100) 2013 Grisold (10.1093/annonc/mdt409_bb0010) 2012; 14 Cornblath (10.1093/annonc/mdt409_bb0035) 1999; 53 Aaronson (10.1093/annonc/mdt409_bb0050) 1993; 85 Cavaletti (10.1093/annonc/mdt409_bb0030) 2003; 61 Inoue (10.1093/annonc/mdt409_bb0065) 2012; 17 Merkies (10.1093/annonc/mdt409_bb0040) 2006; 77 Postma (10.1093/annonc/mdt409_bb0090) 2005; 41 Postma (10.1093/annonc/mdt409_bb0105) 2013; 24 Martina (10.1093/annonc/mdt409_bb0070) 1998; 65 |
| References_xml | – volume: 24 start-page: 1424 year: 2013 end-page: 1426 ident: bb0105 article-title: Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment? publication-title: Ann Oncol – volume: 65 start-page: 743 year: 1998 end-page: 747 ident: bb0070 article-title: Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group publication-title: J Neurol Neurosurg Psychiatry – year: 2013 ident: bb0100 article-title: Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire publication-title: Qual Life Res – volume: 41 start-page: 1135 year: 2005 end-page: 1139 ident: bb0090 article-title: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 publication-title: Eur J Cancer – volume: 20 start-page: 625 year: 2011 end-page: 632 ident: bb0095 article-title: The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA publication-title: Support Care Cancer – volume: 125 start-page: 767 year: 2011 end-page: 774 ident: bb0055 article-title: Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy publication-title: Breast Cancer Res Treat – volume: 14 start-page: iv45 year: 2012 end-page: iv54 ident: bb0010 article-title: Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention publication-title: Neuro Oncol – volume: 53 start-page: 1660 year: 1999 end-page: 1664 ident: bb0035 article-title: Total neuropathy score: validation and reliability study publication-title: Neurology – volume: 77 start-page: 970 year: 2006 end-page: 972 ident: bb0040 article-title: Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies publication-title: J Neurol Neurosurg Psychiatry – volume: 17 start-page: 341 year: 2012 end-page: 347 ident: bb0065 article-title: Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer publication-title: Int J Clin Oncol – volume: 79 start-page: 832 year: 2008 end-page: 834 ident: bb0075 article-title: Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies publication-title: J Neurol Neurosurg Psychiatry – volume: 22 start-page: 2179 year: 2011 end-page: 2190 ident: bb0085 article-title: Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations publication-title: Ann Oncol – volume: 20 start-page: 2959 year: 2012 end-page: 2967 ident: bb0060 article-title: Impact of oxaliplatin-induced neuropathy: a patient perspective publication-title: Support Care Cancer – volume: 12 start-page: 210 year: 2007 end-page: 215 ident: bb0025 article-title: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale publication-title: J Peripher Nerv Syst – volume: 16 start-page: 228 year: 2011 end-page: 236 ident: bb0015 article-title: Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale publication-title: J Peripher Nerv Syst – volume: 46 start-page: 479 year: 2010 end-page: 494 ident: bb0020 article-title: Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools publication-title: Eur J Cancer – volume: 61 start-page: 1297 year: 2003 end-page: 1300 ident: bb0030 article-title: Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale publication-title: Neurology – volume: 24 start-page: 454 year: 2013 end-page: 462 ident: bb0045 article-title: The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings publication-title: Ann Oncol – volume: 33 start-page: 159 year: 1977 end-page: 174 ident: bb0080 article-title: The measurement of observer agreement for categorical data publication-title: Biometrics – volume: 85 start-page: 365 year: 1993 end-page: 376 ident: bb0050 article-title: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology publication-title: J Natl Cancer Inst – volume: 12 start-page: 210 year: 2007 ident: 10.1093/annonc/mdt409_bb0025 article-title: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale publication-title: J Peripher Nerv Syst doi: 10.1111/j.1529-8027.2007.00141.x – volume: 24 start-page: 454 year: 2013 ident: 10.1093/annonc/mdt409_bb0045 article-title: The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings publication-title: Ann Oncol doi: 10.1093/annonc/mds329 – volume: 17 start-page: 341 year: 2012 ident: 10.1093/annonc/mdt409_bb0065 article-title: Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer publication-title: Int J Clin Oncol doi: 10.1007/s10147-011-0298-z – volume: 125 start-page: 767 year: 2011 ident: 10.1093/annonc/mdt409_bb0055 article-title: Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-010-1278-0 – volume: 14 start-page: iv45 issue: Suppl 4 year: 2012 ident: 10.1093/annonc/mdt409_bb0010 article-title: Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention publication-title: Neuro Oncol doi: 10.1093/neuonc/nos203 – volume: 53 start-page: 1660 year: 1999 ident: 10.1093/annonc/mdt409_bb0035 article-title: Total neuropathy score: validation and reliability study publication-title: Neurology doi: 10.1212/WNL.53.8.1660 – volume: 77 start-page: 970 year: 2006 ident: 10.1093/annonc/mdt409_bb0040 article-title: Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients’ own clinical judgement in immune-mediated polyneuropathies publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.2005.076174 – volume: 22 start-page: 2179 year: 2011 ident: 10.1093/annonc/mdt409_bb0085 article-title: Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations publication-title: Ann Oncol doi: 10.1093/annonc/mdq721 – volume: 20 start-page: 2959 year: 2012 ident: 10.1093/annonc/mdt409_bb0060 article-title: Impact of oxaliplatin-induced neuropathy: a patient perspective publication-title: Support Care Cancer doi: 10.1007/s00520-012-1428-5 – volume: 85 start-page: 365 year: 1993 ident: 10.1093/annonc/mdt409_bb0050 article-title: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology publication-title: J Natl Cancer Inst doi: 10.1093/jnci/85.5.365 – volume: 16 start-page: 228 year: 2011 ident: 10.1093/annonc/mdt409_bb0015 article-title: Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale publication-title: J Peripher Nerv Syst doi: 10.1111/j.1529-8027.2011.00351.x – volume: 20 start-page: 625 year: 2011 ident: 10.1093/annonc/mdt409_bb0095 article-title: The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA publication-title: Support Care Cancer doi: 10.1007/s00520-011-1141-9 – volume: 24 start-page: 1424 year: 2013 ident: 10.1093/annonc/mdt409_bb0105 article-title: Prevention of chemotherapy-induced peripheral neuropathy: a matter of personalized treatment? publication-title: Ann Oncol doi: 10.1093/annonc/mdt173 – volume: 41 start-page: 1135 year: 2005 ident: 10.1093/annonc/mdt409_bb0090 article-title: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2005.02.012 – volume: 79 start-page: 832 year: 2008 ident: 10.1093/annonc/mdt409_bb0075 article-title: Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.2007.139220 – year: 2013 ident: 10.1093/annonc/mdt409_bb0100 article-title: Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire publication-title: Qual Life Res doi: 10.1007/s11136-013-0379-8 – volume: 46 start-page: 479 year: 2010 ident: 10.1093/annonc/mdt409_bb0020 article-title: Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools publication-title: Eur J Cancer doi: 10.1016/j.ejca.2009.12.008 – volume: 61 start-page: 1297 year: 2003 ident: 10.1093/annonc/mdt409_bb0030 article-title: Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale publication-title: Neurology doi: 10.1212/01.WNL.0000092015.03923.19 – volume: 33 start-page: 159 year: 1977 ident: 10.1093/annonc/mdt409_bb0080 article-title: The measurement of observer agreement for categorical data publication-title: Biometrics doi: 10.2307/2529310 – volume: 65 start-page: 743 year: 1998 ident: 10.1093/annonc/mdt409_bb0070 article-title: Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.65.5.743 |
| SSID | ssj0006929 |
| Score | 2.4896905 |
| Snippet | The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been... The perception of the severity and relevance of Chemotherapy Induced Peripheral Neurotoxicity (CIPN) is different for physicians and patients. This study... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 257 |
| SubjectTerms | Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use assessment Biological and medical sciences chemotherapy Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction Female Humans Male Medical sciences Middle Aged Neoplasms - drug therapy Nervous system (semeiology, syndromes) Neurology neuropathy neurotoxicity Original Patient Outcome Assessment patient-reported outcome measure Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - pathology Pharmacology. Drug treatments Quality of Life Self Report Treatment Outcome |
| Title | Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin |
| URI | https://dx.doi.org/10.1093/annonc/mdt409 https://www.ncbi.nlm.nih.gov/pubmed/24256846 https://www.proquest.com/docview/1490700755 https://pubmed.ncbi.nlm.nih.gov/PMC3868322 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB7qCiKIeF3rZRlBfKnJtpNJmvi2rMq6UhHdhX0Lk2SCxTZZ2hQv_8F_4I_1m0vSphdYfQlhkklIzjfnMufMN4S8yNIMWl_mTsID4XDOhRP1BXO4D98-yPIhl2qB8-hjcHLOTy_8i07nz0rV0qJK3PTX1nUl_yNVtEGuapXsP0i2eSgacA754ggJ43glGX-qpyUcoXO3MjPr_g1XqmPyAWgsFxVeL3tTMyGoS2AhrKldffXTQWC-UIUAcwS1Kumu6I8138Ckpwkvq_IH3lNpdqjqe9lTe3zO6_KCuZiqkndL4b1BzFwWaWvq_miia7m1--ou8z0Ym1ovN03H5axIJsLM-7xxPzcXRnL2bWy1m_vFPXVXZy4GfGXmwk5BMs9BuMRXtbFZBt1CnVWthsjaWmlmuM83DIAhxxJFgY_DyTSreD9a2ro6v79mApvCRJOS92LzgNh0v0auMwQhOmB__6Gx80HEDJOj_QrL4Iruh6b7oem-y-O5dSnmGIe52UBlW4SzXqi74vmc3SG3bchCjwz-7pKOLO6RGyNblHGf_N6EIQUM6ToMqYUhrWFIxwXdBkNqYUiXMKQtGL6mACHVIKRlTtGdKhBSBcIH5Pzd27PjE8fu8uGk0P-Vk4eDQcKk9DwGZyqTfhIIzkM_HwqRMSEVheUQdjtNoEh8LhIpWCgT7iUhEwIW6iHZw9-WjwiNBPz1aJjxvhQ8ysPI5_DnBYfZyXweDbrkVS2JOLUU-Gonlkm8Ve5d8rK5_dJwv-y6sV-LNbaOq3FIY8ByV5eDlvibF7Bw4ClKqC55XuMhhsZXaTxRyHIxR7AewU7D1fe7ZN_gY9kbJjhASNElwxZymhsUm3z7SjH-qlnlvTBQ1v3xVT_6Cbm5HNRPyV41W8hncNCr5ECPk7-8yvV3 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Physician-assessed+and+patient-reported+outcome+measures+in+chemotherapy-induced+sensory+peripheral+neurotoxicity%3A+two+sides+of+the+same+coin&rft.jtitle=Annals+of+oncology&rft.au=Alberti%2C+P.&rft.au=Rossi%2C+E.&rft.au=Cornblath%2C+D.R.&rft.au=Merkies%2C+I.S.J.&rft.date=2014-01-01&rft.issn=0923-7534&rft.volume=25&rft.issue=1&rft.spage=257&rft.epage=264&rft_id=info:doi/10.1093%2Fannonc%2Fmdt409&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_annonc_mdt409 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon |